Results 1 to 10 of about 50 (49)
Adverse events of raltegravir and dolutegravir [PDF]
AIDS, 2017 To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir.Prospective cohort study.All antiretroviral therapy (ART)-naïve and ART-experienced HIV-infected individuals from the Swiss HIV Cohort Study who initiated raltegravir or dolutegravir between 2006 and 2015 were investigated ...
Elzi, Luigia +8 more
openaire +8 more sources
Hospital Pharmacy, 2014 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada +2 more
openaire +2 more sources
Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis [PDF]
Sexually Transmitted Infections, 2021 ObjectiveTo assess the risk of neuropsychiatric adverse effects (ie, depression, anxiety, insomnia, dizziness, suicidal behaviour) among patients treated with rilpivirine, dolutegravir and dolutegravir/rilpivirine.DesignThis is a systematic review and meta-analysis of randomised controlled trials.
Anthony Allen Reeves +5 more
openaire +2 more sources
Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure [PDF]
Journal of Antimicrobial Chemotherapy, 2018 If HIV patients are unconscious or cannot swallow tablets for other reasons, antiretroviral medication is crushed and dissolved prior to administration. Crushing can alter drug exposure, possibly leading to treatment failure, development of resistance or toxicity.
Marieke Roskam-Kwint +5 more
openaire +4 more sources
BMC Infectious Diseases, 2023 Abstract Dolutegravir (DTG), an integrase strand transfer inhibitor is currently the recommended first and second line anti-retroviral therapy (ART) anchor agent by the World Health Organization. This followed widespread reports of primary resistance to non-nucleoside reverse transcriptase inhibitors.
Mulindwa, Frank +7 more
openaire +5 more sources
Pharmacokinetics and placental transfer of dolutegravir in pregnancy
Journal of Antimicrobial Chemotherapy, 2021 Abstract Dolutegravir is currently recommended by the WHO as the preferred first-line treatment for all people with HIV, including pregnant women. Estimates indicate that, by 2024, nearly 22 million adults in low- and middle-income countries will have transitioned to dolutegravir-based ART.
Mushi Matjila +2 more
openaire +3 more sources
Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir [PDF]
British Journal of Clinical Pharmacology, 2014 AimsThe aim was to evaluate the effect of boceprevir and telaprevir on dolutegravir pharmacokinetics (PK); the effect of dolutegravir on boceprevir and telaprevir PK was assessed through comparison with historical data for each hepatitis C virus (HCV) drug's prescribing information alone.MethodsThis was a single‐centre, randomized, open‐label, two ...
Stephen C. Piscitelli +5 more
openaire +3 more sources
Enhanced Eryptosis Following Exposure to Dolutegravir [PDF]
Cellular Physiology and Biochemistry, 2016 Background/Aims: The viral integrase enzyme inhibitor dolutegravir is utilized for the treatment of immunodeficiency virus (HIV) infection. Knowledge on cytotoxicity of dolutegravir is limited. The present study thus explored, whether dolutegravir is able to trigger suicidal erythrocyte death or eryptosis, which is characterized by cell shrinkage and ...
A. A. M. Bhuyan +3 more
openaire +6 more sources
Psychiatric Symptoms in Patients Receiving Dolutegravir [PDF]
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2017 Introduction: Psychiatric symptoms (PSs) are reported to occur frequently in people living with HIV and may be associated with specific antiretrovirals. We analyzed PSs observed with dolutegravir (DTG) and other frequently prescribed anchor drugs.
Naomi Givens +10 more
openaire +2 more sources
Creation of a long-acting nanoformulated dolutegravir [PDF]
Nature Communications, 2018 AbstractPotent antiretroviral activities and a barrier to viral resistance characterize the human immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir (DTG). Herein, a long-acting parenteral DTG was created through chemical modification to improve treatment outcomes.
Larisa Y. Poluektova +14 more
openaire +3 more sources